Morgan Stanley analyst David Lebovitz maintained a Buy rating on Zealand Pharma A/S (ZEAL) today and set a price target of $30. The company’s shares closed last Monday at $21.15.
According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 5.6% and a 44.0% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, and Blueprint Medicines.
Zealand Pharma A/S has an analyst consensus of Moderate Buy, with a price target consensus of $31, a 43.6% upside from current levels. In a report issued on August 15, Needham also maintained a Buy rating on the stock with a $32 price target.
See today’s analyst top recommended stocks >>
Based on Zealand Pharma A/S’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $20.64 million. In comparison, last year the company had a GAAP net loss of $20.33 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zealand Pharma A/S is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark.
